Mark Alan Goldberg, SVP, Medical&Regulatory Affairs at SYNAGEVA BIOPHARMA CORP (GEVA), sold 7,000 shares at $49.61 ($350K) on 2013-11-01, disclosed to the SEC on 2013-11-04.
Scheduled sale ($350k) by SVP, Medical&Regulatory Affairs under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $49.61 | 3,695 | $183K | 52.4% |
| 2 | $50.34 | 3,205 | $161K | 46.1% |
| 3 | $51.04 | 100 | $5K | 1.5% |
| Total | $49.96 avg | 7,000 | $350K | 100% |
| Filing → |
| BPMC | SELL | 2020-12-22 | $654K | — | Filing → |
| BPMC | SELL | 2020-12-15 | $627K | — | Filing → |
| BPMC | SELL | 2020-12-03 | $600K | — | Filing → |